Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial - 26/09/12
, Ivana Sestak, PhD a, David Cella, PhD b, Lesley Fallowfield, ProfPhD con behalf of the ATAC Trialists’ Group‡
Summary |
Background |
When the mechanism of action behind treatment toxicity reflects the intended effect on the treatment target, the toxicity might be a useful marker for efficacy. During endocrine treatment of breast cancer, the occurrence of symptoms related to oestrogen depletion or oestrogen blockade might thus be a predictor of treatment effectiveness. In this retrospective analysis, the relation between the reported incidence of vasomotor or joint symptoms and breast cancer recurrence in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial is assessed.
Methods |
Women with hormone-receptor-positive tumours who reported vasomotor or joint symptoms at the first follow-up visit (3 months) in the ATAC trial, (which assessed tamoxifen or anastrozole for adjuvant treatment of postmenopausal breast cancer), were compared with women without these symptoms to see if there was a relation between these symptoms and subsequent recurrence. The ATAC trial is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.
Findings |
1486 of 3964 (37·5%) eligible women reported newly emergent vasomotor symptoms at the 3-month follow-up visit and had lower subsequent recurrence than those who did not report these symptoms (223 during 10
752 women-years of follow-up vs 366 during 11573 woman-years of follow-up, respectively; hazard ratio [HR] 0·84 [95% CI 0·71–1·00], p=0·04; adjusted for age, body-mass index, previous hormone-replacement therapy, nodal status, tumour size, and tumour grade). A greater decrease in breast-cancer recurrence was seen for the 1245 of 3964 (31·4%) eligible women who reported new joint symptoms at the 3-month follow-up visit compared with those not reporting these symptoms (158 during 9242 women-years of follow-up vs 366 during 11573 women-years of follow-up; adjusted HR 0·60 [0·50–0·72], p<0·0001).
Interpretation |
The appearance of new vasomotor symptoms or joint symptoms within the first 3 months of treatment is a useful biomarker, suggesting a greater response to endocrine treatment compared with women without these symptoms. Awareness of the relation between early treatment-emergent symptoms and beneficial response to therapy might be useful when reassuring patients who present with them, and might help to improve long-term treatment adherence when symptoms cannot be alleviated effectively.
Funding |
Cancer Research UK and AstraZeneca.
Le texte complet de cet article est disponible en PDF.Plan
Vol 9 - N° 12
P. 1143-1148 - décembre 2008 Retour au numéro
Article précédent
- Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study
- Kaoru Kubota, Masaaki Kawahara, Mitsumasa Ogawara, Yutaka Nishiwaki, Kiyoshi Komuta, Koichi Minato, Yuka Fujita, Satoshi Teramukai, Masanori Fukushima, Kiyoyuki Furuse, on behalf of the Japan Multi-National Trial Organisation
- Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up
- Klara Mosterd, Gertruud AM Krekels, Fred HM Nieman, Judith U Ostertag, Brigitte AB Essers, Carmen D Dirksen, Peter M Steijlen, Anton Vermeulen, HAM Neumann, Nicole WJ Kelleners-Smeets
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?